Gilead Sciences News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

11.04.14	Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients (RTTNews)
10.04.14	Gilead's Phase 2 Trials With Sofosbuvir-Based Regimens Show Positive Results (RTTNews)
10.04.14	Gilead Sciences Reports Results From Sovaldi Trial For HCV Retreatment (RTTNews)
08.04.14	IMMU Chugs Along, MNKD Decision Delayed, QCOR Bought Out, Another First For ISR (RTTNews)
07.04.14	Gilead: Ledipasvir/Sofosbuvir Fixed-Dose Combination Granted FDA Priority Review (RTTNews)
03.04.14	CRY Has Reason To Smile, GILD Eyes Japan, ROSG Inks Deal, OxySure Breathes Easy (RTTNews)
27.03.14	EMA Validates Gilead's Marketing Application For LDV/SOF Combination (RTTNews)
14.03.14	Idenix Files Patent Infringement Lawsuits Against Gilead Sciences In Europe (RTTNews)
04.02.14	Gilead Profit Tops Estimates (RTTNews)
04.02.14	Gilead Sciences Q4 Profit Up - Quick Facts (RTTNews)
04.02.14	Earnings Watch For February 4 (BIDU, GILD, UNM, BSX, CLX) (RTTNews)
30.01.14	DEPO Prevails In Markman Hearing, IDIX, KBIO Get Smacked, ONVO Ahead Of Target (RTTNews)
17.01.14	Gilead: European Commission Grants Marketing Authorization For Sovaldi (RTTNews)
13.01.14	Gilead Sciences: FDA Accepts NDA For Idelalisib For Treatment Of Refractory INHL (RTTNews)
19.12.13	ALIM, PSDV Rally After Iluvien News, GILD Lays Out Plan, REGN Gets FDA Date (RTTNews)
18.12.13	Gilead Reports Topline Results From Phase 3 Study Of ION-1, ION-2 And ION-3 (RTTNews)
16.12.13	Health Canada Issues Notice Of Compliance To Gilead Sciences For Sovaldi (RTTNews)
13.12.13	Gilead Sciences Gets FDA Approval For HIV-1 Regimen Complera - Quick Facts (RTTNews)
09.12.13	AUXL, GILD Get Thumbs Up, COV Snaps Up GIVN, KPTI On The Move, PGNX Awaits Data (RTTNews)
09.12.13	Gilead Announces Pivotal Phase 2 Results For Idelalisib In Refractory INHL (RTTNews)
08.12.13	Gilead Reports Interim Phase 2 Results For GS-9973 In Previously Treated CLL (RTTNews)
06.12.13	Gilead: FDA Okays Sovaldi To Treat Chronic Hepatitis C (RTTNews)
02.12.13	Idenix Files Patent Infringement, Interference Lawsuits Against Gilead (RTTNews)
22.11.13	Gilead Says CHMP Adopts Positive Opinion For Sovaldi - Quick Facts (RTTNews)
18.11.13	Gilead To Present Idelalisib Phase 3 Study At American Society Of Hematology (RTTNews)
18.11.13	Gilead Says EC Approves HIV-1 Treatment Vitekta - Update (RTTNews)
18.11.13	EU Oks Gilead Sciences' Vitekta To Treat HIV-1 Infection - Quick Facts (RTTNews)
29.10.13	Gilead Sciences Q3 Adj. Profit Tops View - Quick Facts (RTTNews)
25.10.13	FDA Panel Backs Gilead's Hepatitis C Drug Sofosbuvir (RTTNews)
22.10.13	Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics (PR Newswire)
21.10.13	Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer (PR Newswire)
16.10.13	Gilead Sciences Reports Study Results On Single Tablet HIV Regimen Stribild (RTTNews)
14.10.13	Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad, Puma Biotechnology, and Dyax (PR Newswire)
11.10.13	Critical Alerts For Gilead Sciences, Chesapeake Energy, Tesoro Corp, Pharmacyclics, and Synaptics Released By InvestorsObserver (PR Newswire)
11.10.13	Technical Study: Gilead Sciences Inc., NPS Pharmaceuticals Inc., Halozyme Therapeutics Inc., and InterMune Inc. (PR Newswire)
10.10.13	Gilead Stops Cancer Drug Trial Early On Positive Results (RTTNews)
09.10.13	Gilead Sciences To Stop Phase III Study Of Idelalisib - Quick Facts (RTTNews)
01.10.13	License Agreements, Strategic Partnerships, Regulatory Approvals, Acquisitions and Sale of Senior Notes - Research Report on Johnson & Johnson, Amgen, Gilead, MAKO, and Edwards Lifesciences (PR Newswire)
26.09.13	Application for Regulatory Approvals, Conferences and Presentations, and Enrollment in Clinical Trials - Research Report on Gilead, Alnylam, Omeros, PTC, and Stemline (PR Newswire)
25.09.13	Gilead Says European Commission Granted Marketing Authorization For Tybost (RTTNews)
20.09.13	Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers (PR Newswire)
17.09.13	Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien (PR Newswire)
16.09.13	Collaborations, New Studies, and New Drug Applications - Research Report on Amgen, Gilead, Abbott, Biogen Idec, and UnitedHealth (PR Newswire)
12.09.13	Gilead's TAF Based Single Tablet HIV Regimen Maintains High Viral Suppression (RTTNews)
12.09.13	Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc. (PR Newswire)
12.09.13	UTHR, FLML Get Review Date, RTIX Facility Passes FDA Inspection, VTUS On Watch (RTTNews)
11.09.13	Gilead Sciences Submits New-drug Application For Idelalisib - Quick Facts (RTTNews)
10.09.13	Critical Alerts For Amazon, Gilead Sciences, Viacom, Broadcom, and MannKind Released By InvestorsObserver (PR Newswire)
09.08.13	Critical Alerts For Disney, Merck, Whole Foods, Gilead Sciences, and Express Scripts Released By InvestorsObserver (PR Newswire)
06.08.13	Solid Margins, Financial Strategies, and Earnings Reports Support Long-Term Growth in Biotech - Research Report on Gilead Sciences, Celgene, Onyx Pharmaceuticals, Questcor, and Amgen (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
21.11.24		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
21.11.24		SMI aktuell: SMI präsentiert sich letztendlich fester
21.11.24		SLI aktuell: Anleger lassen SLI letztendlich steigen
21.11.24		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
21.11.24		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus
21.11.24		Schwache Performance in Zürich: SPI notiert nachmittags im Minus

21.11.24

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

21.11.24

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

21.11.24

SMI aktuell: SMI präsentiert sich letztendlich fester

21.11.24

SLI aktuell: Anleger lassen SLI letztendlich steigen

21.11.24

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

21.11.24

Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus